Angiogenic Switches Play a Critical Progression in Cancer

Nozlena A Samad ^a*, Ahmad Bustamam Abdul ^b, Rasedee Abdullah ^b, Heshu Rahman ^b,d,e KZ Khor ^a, Max Stanley Chartrand  ^c

The role of angiogenesis in tumor development and operating this very particular switch in controlling tumor.    

Abstract

Tumor angiogenesis has become an important research area over the last decade for its crucial role as an essential component of the growth and spread of cancer. A large amount of literature has shown the link between tumor angiogenesis, metastasis, and overall survival of patients. Not all tumors are angiogenesis-derived and the angiogenesis switch is a sign of the ability of tumor and inflammatory cells to produce angiogenesis factors in tumor microenvironment. The condition of genetic stability of endothelial cells plays an important role in this phenomenon as it makes it less likely to build up resistance towards agents aimed at tumor vasculature. Also, the fact that only 0.05% of the adult human body undergoes angiogenesis, the potential side effects of anti-angiogenesis treatment is kept at a minimum. The study, hence, focuses on the role of angiogenesis in tumor development and operating this very particular switch in controlling tumor.    

Keywords: Angiogenesis; Metastasis; Tumors

References

Ahmad S, Cudmore MJ, Wang K, Hewett P, Potluri R, Fujisawa T, et al. (2010). Angiopoietin-1 induces migration of monocytes in a tie-2 and integrin-independent manner. Hypertension, 56(3), 477–83.
https://doi.org/10.1161/HYPERTENSIONAHA.110.155556
PMid:20696992
 
Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN. (2004). The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J ClinPathol. 2004 Aug;57(8):856–60.
https://doi.org/10.1136/jcp.2003.013110
PMid:15280408 PMCid:PMC1770397
 
Baron-Menguy C, Bocquet A, Guihot A-L, Chappard D, Amiot M-J, Andriantsitohaina R, et al. (2007). Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses antiangiogenic. FASEB J., (13), 3511–21.
https://doi.org/10.1096/fj.06-7782com
PMid:17595348
 
Böhm F, Speicher T, Hellerbrand C, Dickson C, Partanen JM, Ornitz DM, et al. (2010). FGF receptors 1 and 2 control chemically induced injury and compound detoxification in regenerating livers of mice. Gastroenterology, 139(4), 1385–96.
https://doi.org/10.1053/j.gastro.2010.06.069
PMid:20603121 PMCid:PMC2949525
 
Brindle NPJ, Saharinen P, Alitalo K. (2006). Signaling and functions of angiopoietin-1 in vascular protection. Circ Res., 98(8), 1014–23.
https://doi.org/10.1161/01.RES.0000218275.54089.12
PMid:16645151 PMCid:PMC2270395
 
Burri PH, Hlushchuk R, Djonov V. (2004). Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. DevDyn, 231(3), 474–88.
https://doi.org/10.1002/dvdy.20184
 
Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. (2011). In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci. 16, 803–14.
https://doi.org/10.2741/3721
 
Chang SC, Ding JL. (2014). Ubiquitination by SAG regulates macrophage survival/death and immune response during infection. Cell Death Differ. Macmillan Publishers Limited.
 
Daly ME. (2003). Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment? Cancer Spectrum Knowl Environ., 95(22), 1660–73.
https://doi.org/10.1093/jnci/djg101
 
Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, et al. (2004). Dosagesensitive requirement for mouse Dll4 in artery development. Genes Dev., 18(20), 2474–8.
https://doi.org/10.1101/gad.1239004
PMid:15466159 PMCid:PMC529534
 
Dudley AC. (2012). Tumor endothelial cells. Cold Spring HarbPerspect Med., 2(3).
https://doi.org/10.1101/cshperspect.a006536
PMid:22393533 PMCid:PMC3282494
 
Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, et al. (2011). Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models. Neoplasia, 13(1), 49–59.
https://doi.org/10.1593/neo.101162
PMid:21245940 PMCid:PMC3022428
 
Fan F, Schimming A, Jaeger D, Podar K. (2012). Targeting the tumor microenvironment: focus on angiogenesis. J Oncol., 281261.
https://doi.org/10.1155/2012/281261
PMid:21876693 PMCid:PMC3163131
 
Folkman J. (2002). Role of angiogenesis in tumor growth and metastasis. SeminOncol., 29(6), 15–8.
https://doi.org/10.1016/S0093-7754(02)70065-1
 
Gaulin J, Kotb R, Turcotte E, Berard G, Sawan B, Schmutz G, et al. (2009). Efficacy of thirdline therapy using bevacizumab in a patient with metastatic colorectal cancer. CurrOncol., 16(5), 84–6.
PMid:19862366 PMCid:PMC2768516
 
Ghosh G, Subramanian I V, Adhikari N, Zhang X, Joshi HP, Basi D, et al. (2010). Hypoxiainduced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest., 120(11), 4141–54.
https://doi.org/10.1172/JCI42980
PMid:20972335 PMCid:PMC2964978
 
Gillies RJ, Gatenby RA. (2007). Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev., 26(2), 311–7.
https://doi.org/10.1007/s10555-007-9065-z
PMid:17404691
 
Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S. (2011). Angiogenesis and multiple myeloma. Cancer Microenviron., 4(3), 325–37.
https://doi.org/10.1007/s12307-011-0072-9
PMid:21735169 PMCid:PMC3234322
 
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev., 91(3), 1071–121.
https://doi.org/10.1152/physrev.00038.2010
PMid:21742796 PMCid:PMC3258432
 
Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, et al. (2009). Chemoattractantsignaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One, 4(8), e6713.
https://doi.org/10.1371/journal.pone.0006713
PMid:19696929 PMCid:PMC2725301
 
Griffioen AW, Molema G. (2000). Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation. Pharmacol Rev., 52(2), 237–68.
PMid:10835101
 
Gupta SC, Kim JH, Prasad S, Aggarwal BB. (2010). Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev, 29(3), 405–34.
https://doi.org/10.1007/s10555-010-9235-2
PMid:20737283 PMCid:PMC2996866
 
Gutiérrez J, Brandan E. (2010). A novel mechanism of sequestering fibroblast growth factor 2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Mol Cell Biol., 30(7), 1634–49.
https://doi.org/10.1128/MCB.01164-09
PMid:20100867 PMCid:PMC2838066
 
Heinke J, Patterson C, Moser M. (2012). Life is a pattern: vascular assembly within the embryo. Front Biosci, 4, 2269–88.
https://doi.org/10.2741/e541
 
Hirota K, Semenza GL. (2006). Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev OncolHematol., 59(1), 15–26.
https://doi.org/10.1016/j.critrevonc.2005.12.003
PMid:16716598
 
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. (2004). Vascular endothelial growth factor and angiogenesis. Pharmacol Rev., 56(4), 549–80.
https://doi.org/10.1124/pr.56.4.3
PMid:15602010
 
Kanthou C, Tozer GM. (2009). Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J ExpPathol., 90(3), 284–94.
https://doi.org/10.1111/j.1365-2613.2009.00651.x
 
Kerbel RS, Kamen BA. (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4(6), 423–36.
https://doi.org/10.1038/nrc1369
PMid:15170445
 
Kerbel RS. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21(3), 505–15.
https://doi.org/10.1093/carcin/21.3.505
 
Kerbel RS. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis, 21(3), 505–15.
https://doi.org/10.1093/carcin/21.3.505
 
Khan N, Mukhtar H. (2010). Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev., 29(3), 435–45.
https://doi.org/10.1007/s10555-010-9236-1
PMid:20714789 PMCid:PMC3142888
 
Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. (2003). Tumor hypoxia: A target for selective cancer therapy. Cancer Sci., 94(12), 1021–8.
https://doi.org/10.1111/j.1349-7006.2003.tb01395.x
PMid:14662015
 
List AF. (2001). Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies. Oncologist, 6(90005), 24–31.
https://doi.org/10.1634/theoncologist.6-suppl_5-24
 
Loges S, Schmidt T, Carmeliet P. (2010). Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer, 1(1), 12–25.
https://doi.org/10.1177/1947601909356574
PMid:21779425 PMCid:PMC3092176
 
Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008 Dec;7(12):3670–84.
https://doi.org/10.1158/1535-7163.MCT-08-0715
PMid:19074844 PMCid:PMC2637411
 
Maiti R. (2014). Metronomic chemotherapy. J Pharmacol Pharmacother., 5(3), 186.
https://doi.org/10.4103/0976-500X.136098
PMid:25210398 PMCid:PMC4156829
 
Mangi MH, Newland AC. (2008). Angiogenesis and Angiogenic Mediators In Haematology Malignancies. Br J Haematol., 111(1), 43–51.
https://doi.org/10.1111/j.1365-2141.2000.02104.x
 
Manjamalai A, Grace, B. (2013). Chemotherapeutic Effect of Essential Oil of Wedeliachinensis (Osbeck) on Inducing Apoptosis, Suppressing Angiogenesis and Lung Metastasis in C57BL/6 Mice Model. J Cancer SciTher., 5, 271-281.
https://doi.org/10.4172/1948-5956.1000216
 
McMahon G. (2000). VEGF Receptor Signaling in Tumor Angiogenesis. Oncologist, 5(90001), 3–10.
https://doi.org/10.1634/theoncologist.5-suppl_1-3
PMid:10804084
 
Moroney JW, Sood AK, Coleman RL. (2009). Aflibercept in epithelial ovarian carcinoma. Future Oncol., 5(5), 591–600.
https://doi.org/10.2217/fon.09.35
PMid:19519199 PMCid:PMC2744352
 
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13(1), 9–22.
https://doi.org/10.1096/fasebj.13.1.9
PMid:9872925
 
Nicosia RF. (1998). What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol., 153 (1), 11–6.
https://doi.org/10.1016/S0002-9440(10)65539-3
 
Nielsen T, Wittenborn T, Horsman MR. (2012). Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics, 4(4), 563–89.
https://doi.org/10.3390/pharmaceutics4040563
PMid:24300371 PMCid:PMC3834929
 
Owen JL, Mohamadzadeh M. (2013). Macrophages and chemokines as mediators of angiogenesis. Front Physiol. Frontiers, 4, 159.
https://doi.org/10.3389/fphys.2013.00159
 
Raga DD, Alimboyoguen AB, Shen C-C, Herrera AA, Ragasa CY. (2011). Triterpenoids and an Anti-Angiogenic Sterol from Ardisiapyramidalis (Cav.) Pers. The Philippine Agricultural Scientist.
 
Reinhart-King C. (2012). Mechanical and Chemical Signaling in Angiogenesis. Springer Science & Business Media.
 
Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. (2003). Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia, 17(10), 1961–6.
https://doi.org/10.1038/sj.leu.2403076
PMid:14513045
 
Ribatti D, Crivellato E. (2012). "Sprouting angiogenesis", a reappraisal. Dev Biol., 372(2), 157–65.
https://doi.org/10.1016/j.ydbio.2012.09.018
PMid:23031691
 
Risinger AL, Giles FJ, Mooberry SL. (2009). Microtubule dynamics as a target in oncology. Cancer Treat Rev., 35(3), 255–61.
https://doi.org/10.1016/j.ctrv.2008.11.001
PMid:19117686 PMCid:PMC2778221
 
Sang QX. (1998). Complex role of matrix metalloproteinases in angiogenesis. Cell Res. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 8(3), 171–7.
 
Saraswati S, Kanaujia PK, Kumar S, Kumar R, Alhaider AA. (2013). Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophoraindica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2mediated angiogenesis. Mol Cancer., 12(1), 82.
https://doi.org/10.1186/1476-4598-12-82
PMid:23895055 PMCid:PMC3733984
 
Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C. (2013). Aflibercept in wet AMD: specific role and optimal use. Drug Des DevelTher., 7, 711–22.
https://doi.org/10.2147/DDDT.S40215
 
Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE. (2004). Current methods for assaying angiogenesis in vitro and in vivo. Int J ExpPathol., 85(5), 233–48.
https://doi.org/10.1111/j.0959-9673.2004.00396.x
 
Stenmark KR, Fagan KA, Frid MG. (2006). Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res., 99(7), 675–91.
https://doi.org/10.1161/01.RES.0000243584.45145.3f
PMid:17008597
 
Sureram S, Senadeera SPD, Hongmanee P, Mahidol C, Ruchirawat S, Kittakoop P. (2012). Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacoratriandra against multidrug-resistant isolates of Mycobacterium tuberculosis. Bioorg Med ChemLett., 22(8), 2902–5.
https://doi.org/10.1016/j.bmcl.2012.02.053
PMid:22418278
 
Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J InvestigDermatolSymp Proc., 5(1), 40–6.
https://doi.org/10.1046/j.1087-0024.2000.00014.x
PMid:11147674
 
Ucuzian AA, Gassman AA, East AT, Greisler HP. (2010). Molecular mediators of angiogenesis. J Burn Care Res., 31(1), 158–75.
https://doi.org/10.1097/BCR.0b013e3181c7ed82
PMid:20061852 PMCid:PMC2818794
 
Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. (2001). Bone marrow angiogenesis in patients with active multiple myeloma. SeminOncol., 28(6), 543–50.
https://doi.org/10.1016/S0093-7754(01)90022-3
 
Vaupel P. (2004). The role of hypoxia-induced factors in tumor progression. Oncologist, 5, 10–7.
https://doi.org/10.1634/theoncologist.9-90005-10
PMid:15591418
 
Verheul HM, Pinedo HM. (2000). The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer. 1, S80–4.
https://doi.org/10.3816/CBC.2000.s.015
PMid:11970755
 
Voelkel NF, Rounds sharon. (2009). The Pulmonary Endothelium: Function in Health and Disease.
 
Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, et al. (2013). LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature, 499(7458), 306–11.
https://doi.org/10.1038/nature12345
PMid:23868260 PMCid:PMC3836402
 
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol., 143(2), 401–9.
PMid:7688183 PMCid:PMC1887042
 
Weston BS. (2003). CTGF Mediates TGF- -Induced Fibronectin Matrix Deposition by UpregulatingActive 5 1 Integrin in Human Mesangial Cells. J Am SocNephrol., 14(3), 601–10.
https://doi.org/10.1097/01.ASN.0000051600.53134.B9
PMid:12595495
 
Yano S, Nishioka Y, Goto H, Sone S. (2003). Molecular mechanisms of angiogenesis in nonsmall cell lung cancer, and therapeutics targeting related molecules. Cancer Sci., 94(6), 479–85.
https://doi.org/10.1111/j.1349-7006.2003.tb01469.x
PMid:12824870
 
Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. (1997). Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol., 17(7), 4015–23.
https://doi.org/10.1128/MCB.17.7.4015
PMid:9199336 PMCid:PMC232254
 
Yuan HT, Khankin E V, Karumanchi SA, Parikh SM. (2009). Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol., 29(8), 2011–22.
https://doi.org/10.1128/MCB.01472-08
PMid:19223473 PMCid:PMC2663314
 
Zou H, Otani A, Oishi A, Yodoi Y, Kameda T, Kojima H, et al. (2010). Bone marrow-derived cells are differentially involved in pathological and physiological retinal angiogenesis in mice. BiochemBiophys Res Commun., 391(2), 1268–73.
https://doi.org/10.1016/j.bbrc.2009.12.057
PMid:20006575